Adhera Therapeutics (MRNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. Based on its drug discovery platform, SMARTICLES Adhera develops proprietary single and double-stranded nucleic acid therapeutics including microRNA mimics, siRNAs, antagomirs and antisense compounds envisioned to activate various RNA-based mechanisms of action. The company is developing CEQ508 in Phase I clinical studies for treating patients with familial adenomatous polyposis (FAP). Adhera is headquartered in City of Industry, California, the US.

Adhera Therapeutics (MRNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Marina Biotech Acquires Prestalia from Symplmed Pharma 12
Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13
Venture Financing 14
Marina Biotech Raises USD0.3 Million in Financing Round 14
Partnerships 15
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Marina Biotech Enters Into Co-Development Agreement With Girindus 17
Merger 18
Marina Biotech and IthenaPharma Merges 18
Licensing Agreements 19
Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19
Oncotelic Enters into Licensing Agreement with Marina Biotech 20
LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21
Autotelic Enters into Licensing Agreement with Marina Biotech 22
Marina Biotech Enters into Licensing Agreement with Autotelic 23
Marina Biotech Enters into Licensing Agreement for NOV582 24
Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25
Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26
Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27
Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28
Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30
Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33
Equity Offering 34
Marina Biotech Raises USD11.7 Million in Private Placement 34
Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35
Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36
Marina Biotech Raises USD6 Million in Private Placement Of Shares 37
Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38
Marina Biotech Completes Private Placement Of Shares For US$2 Million 39
Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 40
Debt Offering 41
Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41
Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42
Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43
Asset Transactions 44
Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44
Adhera Therapeutics - Key Competitors 45
Adhera Therapeutics - Key Employees 46
Adhera Therapeutics - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Corporate Communications 48
Aug 06, 2018: Marina Biotech appoints Jay D. Schwartz to serve as senior vice president, commercial operations 48
Jun 29, 2018: Marina Biotech Names Uli Hacksell And Robert C. Moscato As Board Directors 49
Jun 20, 2018: Marina Biotech Appoints Robert Moscato to Chief Executive Officer 50
Jul 05, 2017: Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman 51
Jun 26, 2017: Marina Biotech appoints chief commercial officer 52
Feb 21, 2017: Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer 53
Feb 14, 2017: Marina Biotech Announces Key Additions to its Executive Management Team 54
Product News 55
03/13/2017: Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16 55
Other Significant Developments 56
Apr 05, 2017: Marina Biotech Provides Business Update 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List Of Tables


Adhera Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 9
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marina Biotech Acquires Prestalia from Symplmed Pharma 12
Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13
Marina Biotech Raises USD0.3 Million in Financing Round 14
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Marina Biotech Enters Into Co-Development Agreement With Girindus 17
Marina Biotech and IthenaPharma Merges 18
Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19
Oncotelic Enters into Licensing Agreement with Marina Biotech 20
LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21
Autotelic Enters into Licensing Agreement with Marina Biotech 22
Marina Biotech Enters into Licensing Agreement with Autotelic 23
Marina Biotech Enters into Licensing Agreement for NOV582 24
Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25
Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26
Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27
Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28
Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30
Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33
Marina Biotech Raises USD11.7 Million in Private Placement 34
Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35
Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36
Marina Biotech Raises USD6 Million in Private Placement Of Shares 37
Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38
Marina Biotech Completes Private Placement Of Shares For US$2 Million 39
Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 40
Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41
Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42
Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43
Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44
Adhera Therapeutics, Key Competitors 45
Adhera Therapeutics, Key Employees 46
Adhera Therapeutics, Subsidiaries 47

List Of Figures


Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adhera Therapeutics (ATRX) - Strategic SWOT Analysis Review

Adhera Therapeutics (ATRX) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

Adhera Therapeutics (MRNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using

USD 250 View Report

Adhera Therapeutics (ATRX) - Strategic SWOT Analysis Review

Adhera Therapeutics (ATRX) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available